Stryker has completed its acquisition of Becton Dickinson's CareFusion portfolio of vertebral compression fracture products. The deal, struck in March 2015, is the latest in Stryker's M&A rampage, and the fourth acquisition closed this month.
Cartiva got a go-ahead in the path toward a potential PMA approval for its Synthetic Cartilage Implant (SCI) to treat osteoarthritis at the base of the great toe. The FDA's Orthopaedic and Rehabilitation Devices Panel voted in support of Cartiva SCI efficacy, safety and that its benefits outweigh its risks. The SCI implant could offer an alternative to a joint fusion approach.
Point-of-care diagnostics maker Alere is struggling under the weight of foreign corruption probes. And Abbott CEO Miles White doesn't know if he wants to bear the load. On a Q1 earnings call, the med tech helmsman declined to affirm his commitment to closing Abbott's previously announced deal for Alere, saying that it was "not appropriate" to comment.
Two years ago, Medtronic rolled out its Reveal Linq, a tiny implantable cardiac monitor, with annual sales predictions to the tune of $1 billion to $2 billion. Now, the company is reporting one-year data from a real-world study of the device showing that it was better at detecting atrial fibrillation than previously thought.
Dx Digest: Quest rolls out new hep C testing services; Foundation Medicine trots out new pediatric cancer data
In this week's Dx Digest, Quest Diagnostics launched hepatitis C test services that help doctors see how patients will respond to certain antiviral therapies, Foundation Medicine revealed new data from more than 1,200 pediatric cancers that could come in handy for developing new drugs for the disease, and Invitae got Medicare reimbursement for its multigene hereditary cancer tests.
Enterome Bioscience has raised €14.5 million ($16.4 million) in a Series C financing led by strategic investor Nestlé Health Science.
Owens & Minor said that one of its major customers would not renew its existing distribution agreement. That customer represented a whopping $525 million in revenues for the company last year; the transition of the customer, an undisclosed national healthcare provider, is expected to start late in 2016.
Auris Surgical Robotics said it will buy minimally invasive robotic surgery company Hansen Medical in a deal valued at about $80 million.
Beleaguered Novartis vision business Alcon is looking for a turnaround. It's been placing some bets on innovation to help it do so in the long term. Now, the vision care specialist has partnered with--and invested in--fluid intraocular lens implant company PowerVision. Alcon also gained an option to acquire the Belmont, CA-based startup as part of the deal.
Medtronic is voluntarily recalling a battery pack used in some of its patient monitors due to a manufacturing defect, adding another piece of bad news to its recent string of woes.
The medical device industry has been working on miniaturizing pacemakers so they can be minimally invasively inserted and cause fewer difficulties for patients. Up next likely are closed-loop systems: pacemakers that record patient data, transmit that data externally and enable adjustment based on that data by physicians or even, eventually, on their own as guided by advanced algorithms.
Johnson & Johnson's medical device sales continued to slide in the first quarter, although the conglomerate, which announced a major medical device business restructuring early this year, was quick to underscore that this effort was on track and going well.
The FDA approved the Personal KinetiGraph in late 2014. The wrist-worn device tracks the movements of Parkinson's disease patients every two minutes over anywhere from 6 to 10 days.
Avedro won FDA approval for its Photrexa Viscous, Photrexa and KXL System to treat corneal collagen cross-linking for the treatment of progressive keratoconus.
Superbug outbreaks tied to duodenoscope devices have caused regulators to step up their oversight of the products. But one lawmaker wants the agency to go even further and is asking Congress to back his efforts.
G-Therapeutics raised €36 million ($41 million) in a Series A round and debt to finish developing and start clinical trials for its Implantable Neuro-stimulation System to restore lower limb function, including walking, to patients suffering from paralysis due to spinal cord injury.
Things keep sliding down a slippery slope for Theranos, and now the beleaguered testing company is sinking even deeper. Federal prosecutors are launching a criminal investigation into Theranos, claiming that the company misled investors about its technology and operations.
IBM's big bet on Watson Health offers little return yet: $4B spent and 6K+ employees added in a year
IBM broke out Watson Health as a separate business unit more than a year ago. It's since poured in a ton of money, with at least four major acquisitions worth a total of $4 billion. Its latest, largest acquisition of Truven Health Analytics just closed last week.
Propeller Health knows that M&A is key to staying ahead in a competitive smart inhaler environment, and the company recently added another deal to its slate. Propeller is teaming up with remote patient monitoring outfit AMC Health to roll out a program aimed at improving drug adherence for individuals with chronic obstructive pulmonary disease (COPD).
Philips, Elekta start to install MRI-guided linear accelerator for next-gen cancer imaging, treatment
Partners Royal Philips and Elekta have started installing a high-field, MRI-guided linear accelerator system at The Netherlands Cancer Institute in Amsterdam. The Institute is part of a consortium founded in 2012 by Elekta and Philips that's slated to make these sorts of systems, known as MR-linac, the standard of care for cancers that are not well controlled.